GLP-1 Approvals, Drug Pricing Battles, and Mark Cuban’s Disruptive Moves in Healthcare with Paige Twenter

In this episode, Paige Twenter, Assistant Editor at Becker’s Hospital Review, joins Scott Becker to discuss the latest developments in the healthcare industry. They dive into the FDA’s recent approval of Ozempic for chronic kidney disease, the soaring costs of GLP-1 medications, and the growing influence of Mark Cuban’s Cost Plus Drug Company in hospital and pharmacy supply chains.